Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials
Incannex shares key developments, including the ongoing clinical trials for its lead product, IHL-42X, in development for the treatment of sleep apnea.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
